Mind Medicine MindMed

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mind Medicine (MNMD) reports robust financials and advances in psychedelic research

Mind Medicine (MNMD) showcased strong financials, R&D progress, and strategic advancements in its Q4 2022 earnings call.
The company's focus on safety, responsible distribution, and talent acquisition positions it well for future growth and innovation.
Challenges in patient enrollment, dosing strategies, and commercialization strategies require strategic planning and clear execution for success.

Mind Medicine (MNMD) reports positive trial data and strong financials

Mind Medicine (MNMD) showcases progress in pipeline development with positive trial results and a strong financial position. The company's focus on advancing treatments for brain health disorders and efficient cash management highlights its commitment to growth and innovation.

MindMed (MNMD) reports Q2 loss, progresses on innovative treatments

MindMed (MNMD) is advancing its R&D pipeline with a focus on MM-120 for GAD and MM-402 for Autism spectrum disorder. Financially, the company maintains a strong position with cash reserves for ongoing operations. Emphasis on placebo-controlled research and innovative formulation technologies highlights a commitment to scientific rigor and product development.

Mind Medicine (MNMD) reports strong financials and promising R&D progress

Mind Medicine (MNMD) is making significant strides in developing innovative treatments for mental health disorders, with promising lead candidates MM-120 and MM-402. While facing increased R&D expenses and analyst scrutiny, the company's strong financial position and focus on unmet needs present opportunities for future growth.

MindMed reports positive Phase IIb results for MM120 in GAD

MindMed's financial performance in 2023 reflected a net loss of $95.7 million but maintained a strong cash position of $99.7 million.
The Phase IIb trial results for MM120 in GAD were positive, demonstrating significant reductions in HAM-A scores and high clinical response rates.
While facing challenges in trial design and demonstrating drug effects, MindMed remains focused on innovation and addressing unmet medical needs.
Opportunities lie in expanding product indications, developing new therapies, and engaging with regulatory authorities to advance their pipeline.

MindMed reports strong Q1 earnings, advances transformative treatments

MindMed's financials remain strong with significant cash reserves and positive trial outcomes for MM-120.
Strategic focus on advancing MM-120 and MM-402 programs while exploring market dynamics and treatment expansion.
Challenges include managing expenses to sustain financial health and interpreting trial data for future research.
Opportunities lie in exploring additional indications, commercial planning, and reshaping patient care with transformative treatments.

MindMed reports strong Q2 earnings, advances Phase III programs

Mind Medicine (MNMD) showcased strong performance in Phase III programs, fundraising, and financials, positioning the company well for future growth and clinical advancements.
With a focus on operational efficiency, patient recruitment, and data integrity, MindMed is poised to address unmet needs in brain health disorders and drive market expansion.
Challenges lie in meeting upcoming milestones, global market analysis, and maintaining data integrity in Phase III trials, but opportunities abound in R&D expansion and market penetration strategies.
Overall, MindMed's strategic focus on Phase III trials, regulatory pathways, and market launch strategies sets a clear path for future success and growth in the brain health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index (NBI), effective at market open on Monday, December 23, 2024. “2024 has been a transformational year for MindMed. We've successfully executed many important milestones, including raising approximately $250 million.

MindMed to Be Added to the Nasdaq Biotechnology Index

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD. Voyage is the first of two Phase 3 studies in GAD evaluating the efficacy and safety of MM120 ODT v.

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company's lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking place December 8 – 11 in Phoenix, AZ. Details of the presentations are a.

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), has been granted an Innovation Passport for the potential treatment of GAD under ILAP by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). The Innovation Passport is the.

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 or.

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 171,000 common shares of the Company (the "Options"), with effective grant dates of November 18, 2024 and December 2, 2024, depending on the a.

MindMed Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company's regulatory and quality functions, as well as its product registration strategies. “We are.

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Jefferies London Healthcare Conference Format: 1x1 Meetings Dates: November 20-21, 2024 Location: London, UK 7th Annual Evercore HealthCONx Conference Format: Fireside.

MindMed to Participate in Upcoming Investor Conferences

Atai Life Sciences BV

AbbVie

COMPASS Pathways

Cybin

President-elect Donald Trump's promise that Robert F Kennedy Junior (RFK Jr) will take on a “big role” in shaping health policy could be a positive for psychedelics given RKF Jr's well-documented support of this drug class, analysts at Jefferies believe. “RFK Jr seems positively inclined and sounds motivated to help foster psychedelic drug development,” analysts wrote in a note to clients, noting that psychedelics have reportedly helped his family and friends recover from trauma, severe depression and obsessive-compulsive disorder.

RFK Jr's appointment in health could accelerate psychedelic drug development, analysts say

Mind Medicine's share price has responded very strongly to a third quarter update that contained very little new information. The market appears to have moved to a bullish stance following confirmation that clinical timelines have not been changed. With a key competitor recently running into difficulties, Mind Medicine may now be the favored play in the psychedelics sector.

Mind Medicine: No News = Good News

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Stephanie Fagan – Chief Corporate Affairs Officer Rob Barrow – Chief Executive Officer Dan Karlin – Chief Medical Officer Conference Call Participants Madhu Yennawar – Leerink Partners James Nevin – RBC Capital Markets Charles Duncan – Cantor Francois Brisebois – Oppenheimer Patrick Trucchio – H.C. Wainwright Michael Okunewitch – Maxim Group Sumant Kulkarni – Canaccord Genuity Operator Good afternoon, and welcome to Mind Medicine Third Quarter 2024 Financial Results and Corporate Update Conference Call.

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended September 30, 2024, and provided a business update. “This is a pivotal moment for MindMed as we prepare to initiate Voyage, our first Phase 3 study of MM120 ODT in GAD,” said Rob Barrow, Chief Executive Officer of MindMed. “B.

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Mind Medicine (MindMed) Inc. is advancing MM-120 for GAD with two phase 3 trials, VOYAGE and PANORAMA, starting in late 2024 and early 2025. MM-120 is also being tested for MDD in the phase 3 EMERGE study, starting in the first half of 2025, with data expected in late 2026. The company has secured funding through 2027, following a public offering, and burns approximately $24.5 million in cash per quarter.

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it plans to host a conference call on Thursday, November 7, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company's results for the third quarter ended September 30, 2024. Listeners can register for the webcast via this link. Analysts wishing t.

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: H.C. Wainwright 26th Annual Global Investment Conference Format: Panel Panel Title: Psychedelics in Psychiatry: Breaking New Ground in Mood Disorders Date and Time: Tue.

MindMed to Participate in September Investor Conferences

Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks.

Psychedelic Stocks: Focus On Their Cash

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 PM ET Company Participants Robert Barrow - CEO Daniel Karlin - CMO Reid Robison - Senior Principal Investigator, Cedar Clinical Research Conference Call Participants Elaine Kim - Cantor Fitzgerald Brian Abrahams - RBC Capital Markets Rudy Li - Leerink Partners LLC Daniel Hultberg - Oppenheimer Christopher Chen - Robert W. Baird Sumant Kulkarni - Canaccord Genuity Operator Good morning, and welcome to the Mind Medicine Second Quarter 2024 Financial Results and Corporate Update Conference Call.

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

MindMed Inc. MNMD, -0.87% said Tuesday it's on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through use of lysergide D-tartrate (LSD) in a clinical setting. MindMed is working on FDA approval for an anxiety therapy using LSD.

MindMed readying Phase III trials for LSD therapy to treat anxiety

Marinus Pharmaceuticals

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense, a leading provider of Modular Open Systems Approach (MOSA) products and mission solutions, announced their team to compete for the U.S. Army's CMOSS Mounted Form Factor (CMFF) program. Led by Pacific Defense, the CMFF team includes state-of-the-art industry technology leaders Thales Defense & Security Inc., BAE, Regal Technology Partners, Palantir and STC, an Arcfield Company. “Our company is purpose-built to drive the open-systems chang.

Pacific Defense Announces US Army CMFF Program Team

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended June 30, 2024, and provided a business update. “Building on the positive momentum from our Phase 2b data for MM120 ODT in GAD, we are excited to be launching our Phase 3 clinical program in GAD later this year and to announce.

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

The Food and Drug Administration rejected Lykos' application to treat PTSD with MDMA therapy. Atai, Compass Pathways, and MindMed are sliding in the wake of the decision.

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 9,285,511 common shares, without par value, at a public offering price of $7.00 per common share, and, to certain investors, pre-funded warrants to purchase 1,428,775 common shares at a price of $6.999 per pre-funded war.

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. All of the common shares and pre-funded warrants are being offered by MindMed. Min.

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

The FDA's decision on MDMA therapy for PTSD is imminent, impacting MindMed investors and the psychedelic medicine industry. An FDA advisory committee voted against approving MDMA therapy, causing market volatility and uncertainty for psychedelic stocks. Major psychedelic stocks like MindMed have the fundamentals and growing FDA support to withstand a negative FDA decision on MDMA therapy.

News for Mind Medicine MindMed Stock (MNMD)